Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective

Drug Resistance Updates

Volumn 13, Issue 1-2, 2010, Pages 29-43

  Verheij, Marcel ^a   Vens, Conchita ^a   van Triest, Baukelien ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Angiogenesis inhibitors; Apoptosis targeting agents; EGFR inhibitors; PARP inhibitors; Radiosensitizer; Radiotherapy; Response prediction; Tyrosine kinase inhibitors

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; AEG 35156; AMIFOSTINE; APO 010; AZD 8055; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CEP 9722; CETUXIMAB; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DEFOROLIMUS; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; HYDROXYUREA; INO 1001; ISOSORBIDE; LAPATINIB; MK 4827; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; N ACETYLCOLCHINOL PHOSPHATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NIMOTUZUMAB; OBATOCLAX; OLAPARIB; PACLITAXEL; PANITUMUMAB; PF 01367338; RADIOSENSITIZING AGENT; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SAR 240550; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ACNE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTENSITY MODULATED RADIATION THERAPY; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; RASH; RECTUM CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; UTERUS CARCINOMA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, INVESTIGATIONAL; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77950867012     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.01.002     Document Type: Article

References (216)

1. Anon. BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium. Cancer Biol. Ther. 8 (2009) 2-3
2. Abdollahi A., Lipson K.E., Han X., et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 63 (2003) 3755-3763
3. Adams R.R., Eckley D.M., Vagnarelli P., et al. Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells. Chromosoma 110 (2001) 65-74
4. Adjei A.A., Cohen R.B., Franklin W., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26 (2008) 2139-2146
5. Aguilar-Quesada R., Munoz-Gamez J.A., Martin-Oliva D., et al. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr. Med. Chem. 14 (2007) 1179-1187
6. Albert J.M., Cao C., Kim K.W., et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 13 (2007) 3033-3042
7. Ali M., Telfer B.A., McCrudden C., et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?. Clin. Cancer Res. 15 (2009) 6106-6112
8. Arizono Y., Yoshikawa H., Naganuma H., Hamada Y., Nakajima Y., and Tasaka K. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Br. J. Cancer 88 (2003) 298-306
9. Ashkenazi A., and Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 118 (2008) 1979-1990
10. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
11. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26 (2008) 3785-3790
12. Augello C., Caruso L., Maggioni M., et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 9 (2009) 125
13. Bartelink H., Roelofsen F., Eschwege F., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J. Clin. Oncol. 15 (1997) 2040-2049
14. Beckert S., Farrahi F., Perveen Ghani Q., et al. IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase. Biochem. Biophys. Res. Commun. 341 (2006) 67-72
15. Belka C., Jendrossek V., Pruschy M., Vink S., Verheij M., and Budach W. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 542-554
16. Belka C., Schmid B., Marini P., et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 20 (2001) 2190-2196
17. Bennett M., Macdonald K., Chan S.W., Luzio J.P., Simari R., and Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282 (1998) 290-293
18. Bernier J., Bentzen S.M., and Vermorken J.B. Molecular therapy in head and neck oncology. Nat. Rev. Clin. Oncol. 6 (2009) 266-277
19. Bianco C., Tortora G., Bianco R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8 (2002) 3250-3258
20. Bischoff J.R., Anderson L., Zhu Y., et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17 (1998) 3052-3065
21. Boehm A.L., Sen M., Seethala R., et al. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol. Pharmacol. 73 (2008) 1632-1642
22. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
23. Bonner, J.A., Harari, P.M., Giralt, J. et al., 2009. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. doi:10.1016/S1470-2045(09)70311-0.
24. Bowman K.J., White A., Golding B.T., Griffin R.J., and Curtin N.J. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br. J. Cancer 78 (1998) 1269-1277
25. Brock W.A., Milas L., Bergh S., Lo R., Szabo C., and Mason K.A. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. 205 (2004) 155-160
26. Brunet A., Roux D., Lenormand P., Dowd S., Keyse S., and Pouyssegur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 18 (1999) 664-674
27. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
28. Buchsbaum D.J., Zhou T., Grizzle W.E., Oliver P.G., Hammond C.J., Zhang S., Carpenter M., and LoBuglio A.F. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 9 (2003) 3731-3741
29. Bushunow P., Reidenberg M.M., Wasenko J., et al. Gossypol treatment of recurrent adult malignant gliomas. J. Neurooncol. 43 (1999) 79-86
30. Calabrese C.R., Almassy R., Barton S., et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 96 (2004) 56-67
31. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl. Cancer Inst. 91 (1999) 2081-2086
32. Camphausen K., Cerna D., Scott T., Sproull M., Burgan W.E., Cerra M.A., Fine H., and Tofilon P.J. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int. J. Cancer 114 (2005) 380-386
33. Camphausen K., and Tofilon P.J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 25 (2007) 4051-4056
34. Camus P., Kudoh S., and Ebina M. Interstitial lung disease associated with drug therapy. Br. J. Cancer 91 Suppl. 2 (2004) S18-S23
35. Cao C., Albert J.M., Geng L., Ivy P.S., Sandler A., Johnson D.H., and Lu B. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res. 66 (2006) 11409-11415
36. Caudell J.J., Sawrie S.M., Spencer S.A., et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int. J. Radiat. Oncol. Biol. Phys. 71 (2008) 676-681
37. Chalmers A.J. The potential role and application of PARP inhibitors in cancer treatment. Br. Med. Bull. 89 (2009) 23-40
38. Chapman J.D., Dugle D.L., Reuvers A.P., Meeker B.E., and Borsa J. Letter: studies on the radiosensitizing effect of oxygen in Chinese hamster cells. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 26 (1974) 383-389
39. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L., Ross B.D., and Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. (U.S.A.) 97 (2000) 1754-1759
40. Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., and Harari P.M. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 223-229
41. Clarke M.J., Mulligan E.A., Grogan P.T., et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol. Cancer Ther. 8 (2009) 407-414
42. Colquhoun A.J., Mchugh L.A., Tulchinsky E., Kriajevska M., and Mellon J.K. Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo. J. Radiat. Res. (Tokyo) 48 (2007) 351-360
43. Crane C.H., Winter K., Regine W.F., Safran H., Rich T.A., Curran W., Wolff R.A., and Willett C.G. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J. Clin. Oncol. 27 (2009) 4096-4102
44. Curtin N.J., Wang L.Z., Yiakouvaki A., et al. Novel poly(ADP-ribose) polymerase-1 inhibitor. AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res. 10 (2004) 881-889
45. Czito B.G., Willett C.G., Bendell J.C., et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J. Clin. Oncol. 24 (2006) 656-662
46. Dai Y., Liu M., Tang W., et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin. Cancer Res. 14 (2008) 7701-7710
47. de Vries E.G., Gietema J.A., and de Jong S. Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin. Cancer Res. 12 (2006) 2390-2393
48. Dean E., Jodrell D., Connolly K., et al. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J. Clin. Oncol. 27 (2009) 1660-1666
49. Dent P., Curiel D.T., Fisher P.B., and Grant S. Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist. Updat. 12 (2009) 65-73
50. Dittmann K., Mayer C., Fehrenbacher B., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 280 (2005) 31182-31189
51. Dittmann K., Mayer C., Kehlbach R., and Rodemann H.P. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol. Cancer 7 (2008) 69
52. Dittmann K., Mayer C., and Rodemann H.P. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother. Oncol. 76 (2005) 157-161
53. Donawho C.K., Luo Y., Luo Y., et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13 (2007) 2728-2737
54. Downs J.A. Chromatin structure and DNA double-strand break responses in cancer progression and therapy. Oncogene 26 (2007) 7765-7772
55. Drew Y., and Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist. Updat. 12 (2009) 153-156
56. Dungey F.A., Loser D.A., and Chalmers A.J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 72 (2008) 1188-1197
57. Eller J.L., Longo S.L., Kyle M.M., Bassano D., Hicklin D.J., and Canute G.W. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 56 (2005) 155-162
58. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
59. Feng F.Y., Lopez C.A., Normolle D.P., et al. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin. Cancer Res. 13 (2007) 2512-2518
60. Flack M.R., Pyle R.G., Mullen N.M., Lorenzo B., Wu Y.W., Knazek R.A., Nisula B.C., and Reidenberg M.M. Oral gossypol in the treatment of metastatic adrenal cancer. J. Clin. Endocrinol. Metab. 76 (1993) 1019-1024
61. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
62. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361 (2009) 123-134
63. Gallo O., Chiarelli I., Boddi V., Bocciolini C., Bruschini L., and Porfirio B. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int. J. Cancer 84 (1999) 573-579
64. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., and Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
65. Geng L., Donnelly E., McMahon G., Lin P.C., Sierra-Rivera E., Oshinka H., and Hallahan D.E. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61 (2001) 2413-2419
66. Geoerger B., Gaspar N., Opolon P., et al. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int. J. Cancer 123 (2008) 209-216
67. Gero D., and Szabo C. Poly(ADP-ribose) polymerase: a new therapeutic target?. Curr. Opin. Anaesthesiol. 21 (2008) 111-121
68. Giaccone G., Zatloukal P., Roubec J., et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J. Clin. Oncol. 27 (2009) 4481-4486
69. Glozak M.A., and Seto E. Histone deacetylases and cancer. Oncogene 26 (2007) 5420-5432
70. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59 (1999) 3374-3378
71. Greco F.A., Bonomi P., Crawford J., et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61 (2008) 82-90
72. Guan B., Yue P., Clayman G.L., and Sun S.Y. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J. Cell. Physiol. 188 (2001) 98-105
73. Gupta A.K., McKenna W.G., Weber C.N., et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 8 (2002) 885-892
74. Gutin P.H., Iwamoto F.M., Beal K., et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 75 (2009) 156-163
75. Haas R.L., de J.D., Valdes Olmos R.A., Hoefnagel C.A., van d.H.I., Zerp S.F., Bartelink H., and Verheij M. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 782-787
76. Hall E.J., and Chapman J.D. Letter: radiosensitization of hypoxic cells with metronidazole. Br. J. Radiol. 47 (1974) 513-514
77. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
78. Hay T., Matthews J.R., Pietzka L., et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res. 69 (2009) 3850-3855
79. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
80. Herbst, R.S., Mendolson, D.S., Ebbinghaus, S. et al., 2006. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J. Clin. Oncol. 24 (18S), Abstract 3013.
81. Hillman R.E., Walsh M.J., Wolf G.T., Fisher S.G., and Hong W.K. Functional outcomes following treatment for advanced laryngeal cancer. Part I--Voice preservation in advanced laryngeal cancer. Part II--Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann. Otol. Rhinol. Laryngol. (Suppl) 172 (1998) 1-27
82. Hoebers F.J., Kartachova M., de B.J., et al. 99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur. J. Nucl. Med. Mol. Imaging 35 (2008) 509-518
83. Horsman M.R., and Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 1518-1523
84. Hotte S.J., Hirte H.W., Chen E.X., et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res. 14 (2008) 3450-3455
85. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59 (1999) 1935-1940
86. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6 (2000) 2166-2174
87. Inoue A., Saijo Y., Maemondo M., et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361 (2003) 137-139
88. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
89. Jain R.K., Duda D.G., Willett C.G., Sahani D.V., Zhu A.X., Loeffler J.S., Batchelor T.T., and Sorensen A.G. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6 (2009) 327-338
90. Jiang B.H., and Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat. 11 (2008) 63-76
91. Kang M.H., and Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 15 (2009) 1126-1132
92. Karikari C.A., Roy I., Tryggestad E., et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol. Cancer Ther. 6 (2007) 957-966
93. Kartachova M., Haas R.L., Olmos R.A., Hoebers F.J., van Z.N., and Verheij M. In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiother. Oncol. 72 (2004) 333-339
94. Kartachova M., van Z.N., Burgers S., van T.H., Verheij M., and Valdes Olmos R.A. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J. Clin. Oncol. 25 (2007) 2534-2539
95. Kartachova M.S., Valdes Olmos R.A., Haas R.L., Hoebers F.J., van H.M., and Verheij M. 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl. Med. Commun. 29 (2008) 39-44
96. Kasten-Pisula U., Windhorst S., hm-Daphi J., Mayr G., and Dikomey E. Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis. Radiother. Oncol. 83 (2007) 296-303
97. Keen N., and Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4 (2004) 927-936
98. Kelland L.R., Burgess L., and Steel G.G. Differential radiosensitization by the poly(ADP-ribose) transferase inhibitor 3-aminobenzamide in human tumor cells of varying radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 14 (1988) 1239-1246
99. Kelley S.K., Harris L.A., Xie D., DeForge L., Totpal K., Bussiere J., and Fox J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299 (2001) 31-38
100. Kitada S., Leone M., Sareth S., Zhai D., Reed J.C., and Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 46 (2003) 4259-4264
101. Kline M.P., Rajkumar S.V., Timm M.M., Kimlinger T.K., Haug J.L., Lust J.A., Greipp P.R., and Kumar S. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp. Hematol. 36 (2008) 568-576
102. Koukourakis M.I., Giatromanolaki A., Sheldon H., Buffa F.M., Kouklakis G., Ragoussis I., Sivridis E., and Harris A.L. Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. Clin. Cancer Res. 15 (2009) 7069-7076
103. Krause M., Ostermann G., Petersen C., et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother. Oncol. 76 (2005) 162-167
104. Krause M., Schutze C., Petersen C., Pimentel N., Hessel F., Harstrick A., and Baumann M. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother. Oncol. 74 (2005) 109-115
105. Krepela E., Dankova P., Moravcikova E., et al. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int. J. Oncol. 35 (2009) 1449-1462
106. Kuijlen J.M., Mooij J.J., Platteel I., Hoving E.W., van der Graaf W.T., Span M.M., Hollema H., and den Dunnen W.F. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J. Neurooncol. 78 (2006) 161-171
107. Kummar S., Kinders R., Gutierrez M.E., et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J. Clin. Oncol. 27 (2009) 2705-2711
108. LaCasse E.C., Mahoney D.J., Cheung H.H., Plenchette S., Baird S., and Korneluk R.G. IAP-targeted therapies for cancer. Oncogene 27 (2008) 6252-6275
109. Lai A., Filka E., McGibbon B., et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int. J. Radiat. Oncol. Biol. Phys. 71 (2008) 1372-1380
110. Lee C.G., Heijn M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60 (2000) 5565-5570
111. Leong S., Cohen R.B., Gustafson D.L., et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J. Clin. Oncol. 27 (2009) 4413-4421
112. Le Tourneau C., Vidal L., and Siu L.L. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist. Updat. 11 (2008) 99-109
113. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
114. Liu G., Kelly W.K., Wilding G., Leopold L., Brill K., and Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin. Cancer Res. 15 (2009) 3172-3176
115. Liu S., Kulp S.K., Sugimoto Y., Jiang J., Chang H.L., Dowd M.K., Wan P., and Lin Y.C. The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anticancer Res. 22 (2002) 33-38
116. Liu X., Han E.K., Anderson M., et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol. Cancer Res. 7 (2009) 1686-1692
117. LoPiccolo J., Blumenthal G.M., Bernstein W.B., and Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11 (2008) 32-50
118. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
119. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345 (2001) 725-730
120. Manegold P.C., Paringer C., Kulka U., et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin. Cancer Res. 14 (2008) 892-900
121. Marini P., Budach W., Niyazi M., Junginger D., Stickl S., Jendrossek V., and Belka C. Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. Int. J. Radiat. Oncol. Biol. Phys. 75 (2009) 198-202
122. Marini P., Schmid A., Jendrossek V., Faltin H., Daniel P.T., Budach W., and Belka C. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 5 (2005) 5
123. Marquardt F., Rodel F., Capalbo G., Weiss C., and Rodel C. Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther. Onkol. 185 (2009) 371-378
124. Milas L., Fan Z., Andratschke N.H., and Ang K.K. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 966-971
125. Milas L., Mason K., Hunter N., Petersen S., Yamakawa M., Ang K., Mendelsohn J., and Fan Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 6 (2000) 701-708
126. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., and Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72 (1993) 835-846
127. Mohammad R.M., Wang S., Aboukameel A., Chen B., Wu X., Chen J., and Al-Katib A. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol. Cancer Ther. 4 (2005) 13-21
128. Mom C.H., Verweij J., Oldenhuis C.N., et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin. Cancer Res. 15 (2009) 5584-5590
129. Mukherjee B., McEllin B., Camacho C.V., et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 69 (2009) 4252-4259
130. Muller M., Wilder S., Bannasch D., et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188 (1998) 2033-2045
131. Ng Q.S., Goh V., Carnell D., Meer K., Padhani A.R., Saunders M.I., and Hoskin P.J. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 67 (2007) 1375-1380
132. Nieder C., Wiedenmann N., Andratschke N.H., Astner S.T., and Molls M. Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. Rev. Recent Clin. Trials 2 (2007) 163-168
133. Nigg E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2 (2001) 21-32
134. Noel G., Godon C., Fernet M., Giocanti N., Megnin-Chanet F., and Favaudon V. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol. Cancer Ther. 5 (2006) 564-574
135. Nyati M.K., Maheshwari D., Hanasoge S., et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res. 10 (2004) 691-700
136. O'Brien S.M., Claxton D.F., Crump M., Faderl S., Kipps T., Keating M.J., Viallet J., and Cheson B.D. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113 (2009) 299-305
137. O'Shaughnessy, J., Osborne, C., Pippen, J. et al., 2009. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J. Clin. Oncol (ASCO Annual Meeting Abstracts) 27, p. 3.
138. Ogasawara J., Watanabe-Fukunaga R., Adachi M., et al. Lethal effect of the anti-Fas antibody in mice. Nature 364 (1993) 806-809
139. Oliver C.L., Bauer J.A., Wolter K.G., et al. In vitro effects of the BH3 mimetic. (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin. Cancer Res. 10 (2004) 7757-7763
140. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
141. Ong F., Moonen L.M., Gallee M.P., ten B.C., Zerp S.F., Hart A.A., Bartelink H., and Verheij M. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother. Oncol. 61 (2001) 169-175
142. Perez-Galan P., Roue G., Villamor N., Campo E., and Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109 (2007) 4441-4449
143. Peter M.E., and Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10 (2003) 26-35
144. Peters N.A., Richel D.J., Verhoeff J.J., and Stalpers L.J. Bowel perforation after radiotherapy in a patient receiving sorafenib. J. Clin. Oncol. 26 (2008) 2405-2406
145. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J. Clin. Oncol. 24 (2006) 1072-1078
146. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355 (2000) 949-955
147. Plastaras J.P., Kim S.H., Liu Y.Y., et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 67 (2007) 9443-9454
148. Plummer R., Attard G., Pacey S., et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13 (2007) 6187-6194
149. Plummer R., Jones C., Middleton M., et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor. AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14 (2008) 7917-7923
150. Plummer, R., Lorigan, P., Evans, J. et al., 2006. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J. Clin. Oncol. (ASCO Annual Meeting Abstracts) 24, p. 8013.
151. Puthalakath H., and Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 9 (2002) 505-512
152. Pyriochou A., Olah G., Deitch E.A., Szabo C., and Papapetropoulos A. Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int. J. Mol. Med. 22 (2008) 113-118
153. Qayum N., Muschel R.J., Im J.H., Balathasan L., Koch C.J., Patel S., McKenna W.G., and Bernhard E.J. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res. 69 (2009) 6347-6354
154. Qiao L., and Wong B.C.Y. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist. Updat. 12 (2009) 55-64
155. Raben D., Helfrich B., Chan D.C., et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res. 11 (2005) 795-805
156. Reed J.C. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst. Mitt. (1996) 72-100
157. Riesterer O., Honer M., Jochum W., Oehler C., Ametamey S., and Pruschy M. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin. Cancer Res. 12 (2006) 3518-3524
158. Roh M.S., Colangelo L.H., O'Connell M.J., et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J. Clin. Oncol. 27 (2009) 5124-5130
159. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., Clarke-Pearson D.L., and Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340 (1999) 1144-1153
160. Rottenberg S., Jaspers J.E., Kersbergen A., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. (U.S.A.) 105 (2008) 17079-17084
161. Saleh M.N., Raisch K.P., Stackhouse M.A., et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFR antibody C225 and radiation. Cancer Biother. Radiopharm. 14 (1999) 451-463
162. Satoh T., Okamoto I., Miyazaki M., et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin. Cancer Res. 15 (2009) 3872-3880
163. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 326 (1992) 524-530
164. Schimmer A.D., O'Brien S., Kantarjian H., et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res. 14 (2008) 8295-8301
165. Seiwert T.Y., Haraf D.J., Cohen E.E., et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J. Clin. Oncol. 26 (2008) 1732-1741
166. Shannon A.M., Telfer B.A., Smith P.D., et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts. Clin. Cancer Res. 15 (2009) 6619-6629
167. She Y., Lee F., Chen J., Haimovitz-Friedman A., Miller V.A., Rusch V.R., Kris M.G., and Sirotnak F.M. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin. Cancer Res. 9 (2003) 3773-3778
168. Shibata T., Noguchi T., Takeno S., Gabbert H.E., Ramp U., and Kawahara K. Disturbed XIAP and XAF1 expression balance is an independent prognostic factor in gastric adenocarcinomas. Ann. Surg. Oncol. 15 (2008) 3579-3587
169. Shintani S., Kiyota A., Mihara M., Sumida T., Kayahara H., Nakashiro K., and Hamakawa H. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Am. J. Clin. Oncol. 26 (2003) e150-e156
170. Singh T.R., Shankar S., Chen X., Asim M., and Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 63 (2003) 5390-5400
171. Stea B., Falsey R., Kislin K., et al. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Lett. 202 (2003) 43-51
172. Stegehuis J.H., de Wilt L.H., de Vries E.G., Groen H.J., de Jong S., and Kruyt F.A. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist. Updat. 13 (2010) 2-15
173. Straughn Jr. J.M., Oliver P.G., Zhou T., Wang W., Alvarez R.D., Grizzle W.E., and Buchsbaum D.J. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol. Oncol. 101 (2006) 46-54
174. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10 (2009) 459-466
175. Taira N., Doihara H., Oota T., et al. Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. Acta Med. Okayama 60 (2006) 25-34
176. Takano T., Ohe Y., Kusumoto M., et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45 (2004) 93-104
177. Tao Y., Zhang P., Girdler F., Frascogna V., Castedo M., Bourhis J., Kroemer G., and Deutsch E. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 27 (2008) 3244-3255
178. Tentori L., Leonetti C., Scarsella M., et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J. 20 (2006) 1709-1711
179. Tentori L., Lacal P.M., Muzi A., et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur. J. Cancer 43 (2007) 2124-2133
180. Thomas G.M. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N. Engl. J. Med. 340 (1999) 1198-1200
181. Thomas H.D., Calabrese C.R., Batey M.A., et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer Ther. 6 (2007) 945-956
182. Thorburn A., Behbakht K., and Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist. Updat. 11 (2008) 17-24
183. Thraves P., Mossman K.L., Brennan T., and Dritschilo A. Radiosensitization of human fibroblasts by 3-aminobenzamide: an inhibitor of poly(ADP-ribosylation). Radiat. Res. 104 (1985) 119-127
184. Tolcher A.W., Mita M., Meropol N.J., et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25 (2007) 1390-1395
185. Tolcher A.W., Mita A., Lewis L.D., et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol. 26 (2008) 5198-5203
186. Tong Y., Bouska J.J., Ellis P.A., et al. Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents. J. Med. Chem. 52 (2009) 6803-6813
187. Trudel S., Stewart A.K., Li Z., et al. The Bcl-2 family protein inhibitor. ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin. Cancer Res. 13 (2007) 621-629
188. Turner N., Tutt A., and Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4 (2004) 814-819
189. Van Poznak C., Seidman A.D., Reidenberg M.M., et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res. Treat. 66 (2001) 239-248
190. Verbrugge I., de V.E., Tait S.W., Wissink E.H., Walczak H., Verheij M., and Borst J. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 27 (2008) 574-584
191. Verbrugge, I., Maas, C., Heijkoop, M., Verheij, M., Borst, J., 2009a. Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation. Cell Death Differ. doi:10.1038/cdd.2009.141.
192. Verbrugge I., Wissink E.H., Rooswinkel R.W., Jongsma J., Beltraminelli N., Dupuis M., Borst J., and Verheij M. Combining radiotherapy with APO010 in cancer treatment. Clin. Cancer Res. 15 (2009) 2031-2038
193. Verheij M., van Blitterswijk W.J., and Bartelink H. Radiation-induced apoptosis-the ceramide-SAPK signaling pathway and clinical aspects. Acta Oncol. 37 (1998) 575-581
194. Veuger S.J., Curtin N.J., Smith G.C., and Durkacz B.W. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 23 (2004) 7322-7329
195. Wakelee, H.A., Patnaik, A., Sikic, B.I. et al., 2009. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann. Oncol. doi:10.1093/annonc/mdp292.
196. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
197. Wang C., Abe S., Matsuda K., Yu C., Li Y., Usuki J., Azuma A., and Kudoh S. Effects of gefitinib on radiation-induced lung injury in mice. J. Nippon Med. Sch. 75 (2008) 96-105
198. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 15 (2001) 2922-2933
199. Weppler S.A., Li Y., Dubois L., Lieuwes N., Jutten B., Lambin P., Wouters B.G., and Lammering G. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother. Oncol. 83 (2007) 333-339
200. Wickenden J.A., Jin H., Johnson M., et al. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 27 (2008) 7150-7161
201. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10 (2004) 145-147
202. Willett C.G., Duda D.G., di Tomaso E., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J. Clin. Oncol. 27 (2009) 3020-3026
203. Williams K.J., Telfer B.A., Brave S., Kendrew J., Whittaker L., Stratford I.J., and Wedge S.R. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin. Cancer Res. 10 (2004) 8587-8593
204. Williams K.J., Telfer B.A., Shannon A.M., Babur M., Stratford I.J., and Wedge S.R. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol. Cancer Ther. 6 (2007) 599-606
205. Williams K.J., Telfer B.A., Stratford I.J., and Wedge S.R. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br. J. Cancer 86 (2002) 1157-1161
206. Wissink E.H., Verbrugge I., Vink S.R., Schader M.B., Schaefer U., Walczak H., Borst J., and Verheij M. TRAIL enhances efficacy of radiotherapy in a p53 mutant. Bcl-2 overexpressing lymphoid malignancy. Radiother. Oncol. 80 (2006) 214-222
207. Wollman R., Yahalom J., Maxy R., Pinto J., and Fuks Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int. J. Radiat. Oncol. Biol. Phys. 30 (1994) 91-98
208. Wolter K.G., Wang S.J., Henson B.S., et al. (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia 8 (2006) 163-172
209. Wright C.W., and Duckett C.S. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J. Clin. Invest. 115 (2005) 2673-2678
210. Wu G.S., Burns T.F., McDonald III E.R., et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17 (1997) 141-143
211. Xu L., Yang D., Wang S., et al. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol. Cancer Ther. 4 (2005) 197-205
212. Zaidi S.H., Huddart R.A., and Harrington K.J. Novel targeted radiosensitisers in cancer treatment. Curr. Drug Discov. Technol. 6 (2009) 103-134
213. Zerp S.F., Stoter R., Kuipers G., et al. AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat. Oncol. 4 (2009) 47
214. Zhang M., Liu H., Guo R., et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem. Pharmacol. 66 (2003) 93-103
215. Zhang M., Liu H., Tian Z., Griffith B.N., Ji M., and Li Q.Q. Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways. Life Sci. 80 (2007) 767-774
216. Zhang N., Erjala K., Kulmala J., Qiu X., Sundvall M., Elenius K., and Grenman R. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother. Oncol. 92 (2009) 388-392